All Discovery Content

Bringing you the latest research in Drug Discovery In New Modalities, Integration Of DEL, Covalent Inhibitors, Protein Degradation Technologies, Computational Drug Design & Automation Strategies and more, through a range of Speaker Interviews, Industry Insights, and Expert Opinions.
Commentary
A Senior Director at AstraZeneca takes us through how the company synthesises and validates novel PROTACs.
By Tom Cohen |
13 May 2022
Targeted Protein Degradation
Insight Article
Oxford Global’s protein degradation panel discussion brought together leading experts in the field to talk about bringing PROTACs to clinical trial endpoints.
By Tom Cohen |
21 April 2022
Targeted Protein Degradation
Discussion Group Report
Govinda Bhisetti, Principal Investigator and Head of Computational Chemistry at Biogen, leads a discussion group on what the revolutionary machine learning technology means for drug design.
By Tom Cohen |
21 April 2022
Computational Drug Design & AI
Commentary
There are innumerable possible compounds in Merck KGaA’s virtual library, so finding drug candidates is only possible with the help of computational methods.
By Tom Cohen |
23 March 2022
Computational Drug Design & AI
Audio Content
Audio Q&A
In conversation with Dr Neil McCarthy, MRC Career Development Fellow, Centre for Immunobiology, The Blizard Institute, Queen Mary University of London.
17 March 2022
Organ Modelling Discovery
Insight Article
Artificial intelligence and machine learning could be an invention comparable to electricity, so what does the future hold for its use in drug discovery?
By Tom Cohen |
16 March 2022
Computational Drug Design & AI
Discussion Group Report
How do scientists secure the tissue they need? Should scientists be careful with the words they use for next generation technologies? And why is validation for organ modelling so important?
By Tom Cohen |
15 March 2022
Organ Modelling Discovery
Discussion Group Report
Our February Discovery Series discussion group centred on DNA Encoded Libraries (DEL). Using DEL enables the simultaneous screening of thousands of potential drugs against a target.
By Oliver Picken |
11 March 2022
Discovery Series
Insight Article
Organoids are three-dimensional tissue cultures grown from stem cells. They have been among the most important and exciting developments in medical sciences in the last decade.
By Oliver Picken |
01 March 2022
Organ Modelling Discovery
Discussion Group Report
Progress in protein degradation has accelerated in the past few years, and 2021 saw several breakthroughs. Efforts to target STAT3, however, have proven to be especially challenging.
By Oliver Picken |
18 February 2022
Targeted Protein Degradation

Search by Keyword

Filter by Subject Area

Filter by Content Type

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Member Community Login